Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$1.39 - $5.58 $10.7 Million - $42.9 Million
-7,695,505 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$2.75 - $6.57 $3.03 Million - $7.23 Million
1,100,000 Added 16.68%
7,695,505 $41 Million
Q4 2020

Feb 16, 2021

SELL
$1.38 - $3.01 $291,828 - $636,524
-211,470 Reduced 3.11%
6,595,505 $17.3 Million
Q3 2020

Nov 16, 2020

SELL
$1.58 - $4.77 $807,117 - $2.44 Million
-510,834 Reduced 6.98%
6,806,975 $11.8 Million
Q1 2020

May 15, 2020

BUY
$2.33 - $12.98 $6.87 Million - $38.3 Million
2,950,000 Added 67.54%
7,317,809 $28.7 Million
Q4 2019

Feb 14, 2020

BUY
$6.75 - $11.15 $5.12 Million - $8.46 Million
758,725 Added 21.02%
4,367,809 $46.7 Million
Q2 2019

Aug 14, 2019

BUY
$7.58 - $10.0 $18.8 Million - $24.8 Million
2,480,560 Added 219.81%
3,609,084 $29.7 Million
Q1 2019

May 15, 2019

BUY
$5.81 - $9.37 $1.75 Million - $2.83 Million
301,564 Added 36.47%
1,128,524 $8.7 Million
Q4 2018

Feb 14, 2019

SELL
$5.75 - $21.85 $12.6 Million - $47.7 Million
-2,183,038 Reduced 72.53%
826,960 $5.31 Million
Q3 2018

Nov 14, 2018

BUY
$16.81 - $24.58 $15.2 Million - $22.2 Million
901,800 Added 42.78%
3,009,998 $67.6 Million
Q2 2018

Aug 14, 2018

BUY
$18.6 - $24.94 $273,420 - $366,618
14,700 Added 0.7%
2,108,198 $40.7 Million
Q1 2018

May 15, 2018

BUY
$20.86 - $26.6 $23.3 Million - $29.7 Million
1,114,879 Added 113.92%
2,093,498 $48.3 Million
Q4 2017

Feb 14, 2018

BUY
$20.9 - $49.36 $8.41 Million - $19.9 Million
402,200 Added 69.78%
978,619 $24.1 Million
Q3 2017

Nov 14, 2017

BUY
$39.62 - $46.17 $22.8 Million - $26.6 Million
576,419
576,419 $24.5 Million

Others Institutions Holding DBVT

About DBV Technologies S.A.


  • Ticker DBVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,776,992
  • Market Cap $175M
  • Description
  • DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...
More about DBVT
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.